Can Rediveway beat the new crown virus? The results of the clinical trial will be seen in April.
Reedivir is being placed with increasing hopes after he has cured a new patient with new coronary pneumonia in France. Can it be the ultimate savior against new coronary pneumonia? On February 17, Gilead explained the clinical trial situation: two experiments are being carried out in several hospitals in Hubei, and the experimental results are expected to be obtained in April.
For clinical trials, Dr. Merdad Parsey, Gilead’s Chief Medical Officer, said in an interview with Xinhua: “With the strong support of Chinese government agencies, we have quickly established two A randomized, controlled trial of Sivir, one for severe patients and the other for patients with moderate symptoms. “
“These two experiments are being carried out in many hospitals in Hubei, and patients are being enrolled. The clinical trials are coordinated by the China-Japan Friendship Hospital. The patients will receive a 10-day intravenous injection of Redecive. The primary endpoints of both studies included improvement in clinical symptoms 28 days after receiving treatment. We expect to obtain trial results in April. “
Redesivir was developed by Gilead, an antiviral drug company, originally used to treat Ebola virus infection. However, since 2017, there have been continuous studies indicating that Redecive may be able to inhibit coronavirus. For SARS and Middle East Respiratory Syndrome (MERS), Radixivir has been shown to have preventive and therapeutic effects in both in vivo and in vitro animal models. The new crown virus is similar in structure to them. Therefore, Redecive is also regarded as one of the most promising drugs for new coronary pneumonia.
Responding to this, Gilead said: “Redesivir is an experimental drug, and so far only a small number of patients infected with neocoronavirus have been used, so the company’s effect on Redesivir is not sufficient. “Understanding, it is not enough to ensure that the drug can be widely used. By comparison with the placebo group, the trial will be able to judge the key issues of the safety and effectiveness of Redecive.”
While Redecive has high hopes, commercial competition has begun. On January 21, the Wuhan Institute of Virology of the Chinese Academy of Sciences declared the invention patent of Radixivir for the 2019 new crown virus (emphasis on the use rather than the structure of the drug itself). On February 15th, a listed company stated that it was developing imitation of Redecide API.
For commercialization issuesGilead’s attitude is encouraging. The company said: “At present, Gilead has not considered the potential commercial value of this drug under investigation. We are now focusing on the potential clinical value that Radixivir may bring to patients and do our best to help fight the new crown virus. Outbreak of pneumonia. Gilead is also in discussions with regulators to determine the most appropriate path for Redecive to obtain approval if clinical trial results are positive.
“Gilead has hundreds of employees working around the clock, doing everything in our power to help fight the epidemic,” said Dr. Merdad Parsey.
With regard to production issues, Gilead said: “Now, our primary consideration is to support clinical trials in China to determine the safety and effectiveness of Redecive in the treatment of New Coronavirus pneumonia. Risks, but given the urgency of the situation, we are also doing our best to accelerate production and increase the availability of Redecive. “
At present, in addition to Gilead, other treatment options have entered the clinical stage: For example, on February 13, Chinese biology used the plasma of recoverers to prepare neocrown virus-exclusive plasma products and exoglobulin, which were used clinically to treat severe diseases. Patient; On February 16th, Hisense Pharma’s fapilavir generic drug was approved for clinical trials of new crown pneumonia. Eventually defeating the new crown pneumonia epidemic may be just around the corner.
Picture from unsplash.com